Cost Analysis of Treating Neonatal Hypoglycemia with Dextrose Gel
| Autor: | Matthew J. Glasgow, Jane E. Harding, Richard Edlin, Jane Alsweiler, J. Geoffery Chase, Deborah Harris, Benjamin Thompson, Trecia Ann Wouldes, Judith Ansell, Anne Jaquiery, Kelly Jones, Sapphire Martin, Christina McQuoid, Jenny Rogers, Heather Stewart, Anna Tottman, Kate Williamson, Ellen Campbell, Coila Bevan, Tineke Crawford, Kelly Fredell, Kate Sommers, Claire Hahnhaussen, Safayet Hossin, Karen Frost, Grace McKnight, Janine Paynter, Jess Wilson, Rebecca Young, Anna Gsell, Jessica Brosnahan, Anna Timmings, Arun Nair, Alexandra Wallace, Phil Weston, Aaron Le Compte, Matthew Signal, Nicola Austin, Jeremy Armishaw, Nicola Webster, Ross Haslam, Pat Ashwood, Lex Doyle, Kate Callanan, Ian Wright, Heidi Feldman, William Hay, Darrell Wilson, Robert Hess |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Neonatal intensive care unit Breastfeeding Hypoglycemia Placebo Article law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law 030225 pediatrics Intensive care medicine Humans 030212 general & internal medicine health care economics and organizations business.industry Neonatal hypoglycemia Decision Trees Infant Newborn Length of Stay medicine.disease Clinical trial Glucose Sweetening Agents Pediatrics Perinatology and Child Health Emergency medicine Costs and Cost Analysis Intensive Care Neonatal Health Resources business Gels New Zealand |
| Popis: | Objective To evaluate the costs of using dextrose gel as a primary treatment for neonatal hypoglycemia in the first 48 hours after birth compared with standard care. Study design We used a decision tree to model overall costs, including those specific to hypoglycemia monitoring and treatment and those related to the infant's length of stay in the postnatal ward or neonatal intensive care unit, comparing the use of dextrose gel for treatment of neonatal hypoglycemia with placebo, using data from the Sugar Babies randomized trial. Sensitivity analyses assessed the impact of dextrose gel cost, neonatal intensive care cost, cesarean delivery rate, and costs of glucose monitoring. Results In the primary analysis, treating neonatal hypoglycemia using dextrose gel had an overall cost of NZ$6863.81 and standard care (placebo) cost NZ$8178.25; a saving of NZ$1314.44 per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, cesarean delivery rates, and costs of monitoring. Conclusions Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycemia. Because it is also noninvasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycemia. Trial registration Australian New Zealand Clinical Trials Registry: ACTRN12608000623392. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|